BiotechTube
Home/DefEYE/Rob Sambursky, MD
RS

Rob Sambursky, MD

Chief Executive Officer

DefEYE

Therapeutic Areas

OphthalmologyOcular Surface Disease

DefEYE Pipeline

DrugIndicationPhase
BIOVANCE 3L OcularOcular surface disease and ocular surgery (e.g., pterygium)Approved